In some welcome good news, "The European Commission has approved a fixed-dose combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL)"
Oh that’s such good news for me (provided the UK follows suit) the numbers look good and it will avoid me having yet another round of chemo with C+O. I might be CLL ‘treatment naive’ but I have had 3 lots of chemo already. I have been told I am likely to be in treatment by the end of this year.
Because this Forum pushes us to see a CLL expert (thank you for that!) I have asked for a 2nd opinion on my treatment options at Barts (no appointment as yet) given my comorbidities and this post gives me ammunition to take to the discussion.
"On 30 January 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product venetoclax (Venclyxto).
:
Venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). "
Yes I have seen that, and understand that it is a recommendation to change the terms etc. It is not confirmation of the EU decision made (I think) 9th March or thereabouts.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.